: In June 2026 Humacyte raised aggregate gross proceeds of $57.5 million from a public offering of its common stock. Second Quarter 2026 Financial HighlightsCommercial sales of Symvess were $0.4 million in the second quarter of 2026 compared to $0.1 million in the second quarter of 2025. For the six months ended June 30 2026, commercial sales of Symvess were $0.9 million compared to $0.2 million for the six months ended June 30, 2025. Cost of goods sold was $3.3 million for the six months ended June 30, 2026 compared to $0.4 million for the six months ended June 30, 2025. In clinical trials of Symvess, patients received antiplatelet therapy following implantation of Symvess to reduce the risk of thrombosis.